A fine inheritance, but it's not all in the bag

Dr Guy Besley, *formerly* Willink Biochemical Genetics Unit, Manchester Children's Hospital, Manchester M27 4HA, UK.

The Willink Unit, Manchester - a fine inheritance





June 1979

Brian Fowler

- Joined George Komrower's group in 1965
- Mental Retardation Unit, Royal Manchester Children's Hospital. Later renamed Willink Biochemical Genetics Unit.
- Working with Michael Griffiths and Ann Lambert to set up screening tests for amino acidaemias. Cath Bridge joined group in 1967
- Gained Higher National Certificate in 1967 and MIBiol in 1970 and subsequently PhD

Brian Fowler

- On MRC travel scholarship
- Research at Yale with Rosenberg, Packman and Kraus on CBS
- Returned to Manchester in 1977
- Continued interest in CBS and MMA
- Willink Unit moved to a purpose-built establishment in 1984
- Left the 'new' Willink Unit in 1990

Phenylketonuria

Patient Images removed

Newborn Screening

- Mental Retardation Unit (RMCH)
- Guthrie test felt to be too limited
- Scriver chromatography would identify other than PKU
- A community pilot survey for amino acidopathies (1967)
- Would this be workable using liquid blood?





Newborn Screening



- Tandem MS purchased in 1998
- Initially used butylated samples for acylcarnitines
- PKU screening in 2001 and MCAD roll out on non-butylated in 2004
- However, continued to look at methionine and branched-chain amino acids
- UK still trying to expand newborn screening

Amino acid Screening

- 2D TLC
- Paper chromatography (iodoplatinate, Pauly and ninhydrin/Ehrlich stains)
- Spot tests
- Labour-intensive but excellent method



Basics Homocystine







2D-urine AA

∧B 1B 3 18 Jul لىر100 🔘 < P <P Cystinuria Hyperprolinaemia 1B TB

1 Ful

Homocystinuria

Lyce @

Tyrosinaemia type I

2D-urine AA



Ornithinaema

Argininosuccinic aciduria

Edinburgh SSIEM 1976





SSIEM Council hard at work June 1989

At ease with Royalty



But a European at heart...



Expanding European interests



ERNDIM and lysosomal EQA

- But it's not all in the bag
- Developing an EQA for lysosomal enzyme assays has proved something of a challenge
- Activities are both cell and substratespecific

Lysosomal function



Evidence of lysosomal storage

Vacuolated cells in blood and bone marrow Cherry-red spot in eye





Lysosomal storage



PAS staining showing ballooned neurones

EM showing MCBs





TLC of brain lipids







Enzyme activities in tissues (nmol/min per mg protein)

Tissue	GM1-β- galactosidase	4MU-β- galactosidase
GM1 brain	0.009	0.33
Control brain	0.49	1.68
GM1 liver	0.007	0.26
Control liver	1.77	3.09

Enzyme activities in fibroblasts (nmol/min per mg protein)

Cells	4MU-β-galactosidase
GM1-gangliosidosis	0.12 and 0.03
Carriers	1.78 and 2.28
Controls	2.5 - 7.5

$4MU \beta$ -galactosidase assay

- Diagnostic assays normally on leukocytes
- Very simple assay
- B-gal usually used as reference enzyme when other lysosomal assays performed
- But the enzyme is a complex containing a protective protein and is stabilised by chloride ions

4MU β-glucosidase assay

- For diagnosis of Gaucher disease
- Hydrophobic membrane-bound enzyme
- Requires activator in vivo
- And *in vitro*, the detergent taurocholate is required for leukocyte assays
- The assay conditions are critical for diagnostic testing

Leukocyte beta-glucosidase

Raghavan et al (1980)



Fig. 2. —Comparison of pH activity curves for leukocyte β -glucosidase in control (O——O), obligate heterozygote (O——O), and patient with Gaucher disease (\bullet —— \bullet) assayed in absence of detergent (A) and presence of 0.2% TDC (B).

4MU acid α -glucosidase assay

- Diagnostic assay for Pompe disease
- Problems using leukocytes due to interference from neutral/renal enzyme
- Can be overcome using lymphocytes or specific inhibitor

Diagnostic lysosomal enzyme assays

- Usually performed on mixed leukocytes and plasma
- A group of enzymes are assayed in parallel
- But a full understanding of specificities and optimum conditions for each are required
- Different methods of enzyme extraction and optimisations used

EQA requirement

- Ideally real samples should be used
- Activities in fibroblasts very different to leukocytes
- Activities in transformed lymphocytes also very different and not normally used
- This is a big challenge!
- Maybe plasma and DBS in the future
- To Kees Schoonderwoerd: Good luck

Munich SSIEM 1989 - Herzogstand



Good-Bye and Good Luck, Brian

